Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
More about Open Access at the CrickAuthors list
E Ghorani Rachel Rosenthal N McGranahan JL Reading M Lynch KS Peggs Charles Swanton SA QuezadaAbstract
Cancer mutations generate novel (neo-)peptides recognised by T cells, but the determinants of recognition are not well characterised. The difference in predicted class I major histocompatibility complex (MHC-I) binding affinity between wild-type and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer.
Journal details
Journal Annals of Oncology
Volume 29
Issue number 1
Pages 271-279
Available online
Publication date
Full text links
Publisher website (DOI) 10.1093/annonc/mdx687
Figshare View on figshare
Europe PubMed Central 29361136
Pubmed 29361136